Abstracts tagged "IgG4"

Abstract Number: 115 • 2019 ACR/ARP Annual Meeting
CD8+ Cytotoxic T Lymphocytes Are Clonally-expanded in IgG4-related Disease and Home to Affected Tissues
Cory Perugino¹, Naoki Kaneko ², Takashi Maehara ², Jesper Kers ³, Hang Liu ⁴, Vinay Mahajan ⁴, Yesim Tuncay ⁴, Zachary Wallace ¹, Lloyd Liang ¹, Sydney Montesi ⁵, John Stone ⁶ and Shiv Pillai ⁷, ¹Massachusetts General Hospital, Boston, ²Kyushu University, Fukuoka, Japan, ³University of Amsterdam, Amsterdam, Netherlands, ⁴Ragon Institute of MGH, MTI and Harvard, Cambridge, ⁵Massachusetts General Hospital, Boston, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁷Ragon Institude of MGH, MIT and Harvard, Charlestown, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic immune-mediated fibrotic disease often causing multi-organ involvement. We have previously reported the association of SLAMF7+ CD4+ cytotoxic T…
Abstract Number: 972 • 2019 ACR/ARP Annual Meeting
Disease Severity Is Linked to an Increase in Autoantibody Diversity in IgG4-related Disease
Hang Liu¹, Cory Perugino ², Musie Ghebremichael ¹, Zachary Wallace ², Sydney Montesi ³, John Stone ⁴ and Shiv Pillai ⁵, ¹Ragon Institute of MGH, MTI and Harvard, Cambridge, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁵Ragon Institude of MGH, MIT and Harvard, Charlestown, MA
Background/Purpose: The oligoclonal expansion in IgG4-related disease (IgG4-RD) of both plasmablasts and tissue-infiltrating CD4+ cytotoxic T lymphocytes, the identification of specific auto-antigens as B cell…
Abstract Number: 2821 • 2019 ACR/ARP Annual Meeting
Clonal Expansion of a Specific Subset of Cytotoxic CD4+T Cells and Tissue Apoptosis in Patients with IgG4-related Disease
Cory Perugino¹, Naoki Kaneko ², Jesper Kers ³, Takashi Maehara ², Hamid Mattoo ⁴, Hang Liu ⁵, Vinay Mahajan ⁵, Musie Ghebremichael ⁵, Hugues Allard-Chamard ⁵, Yesim Tuncay ⁵, Emanuel Della Torre ⁶, Zachary Wallace ¹, Lloyd Liang ¹, Sydney Montesi ⁷, John Stone ⁸ and Shiv Pillai ⁹, ¹Massachusetts General Hospital, Boston, ²Kyushu University, Fukuoka, Japan, ³University of Amsterdam, Amsterdam, Netherlands, ⁴Sanofi, Cambridge, ⁵Ragon Institute of MGH, MTI and Harvard, Cambridge, ⁶Hospital San Raffaele, milan, Italy, ⁷Massachusetts General Hospital, Boston, MA, ⁸Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁹Ragon Institude of MGH, MIT and Harvard, Charlestown, MA
Background/Purpose: In IgG4-related disease (IgG4-RD), both activated B cells and CD4+ cytotoxic T lymphocytes (CD4+CTLs) expand clonally, accumulate in tissues, likely recognize distinct epitopes on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].